Compare Coursera Inc (COUR) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Coursera Inc vs Sanofi SA — how do they compare? Coursera Inc trades at $5.25 (market cap $1.39B), while Sanofi SA trades at $40.05 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 68.5× Coursera Inc's market cap, and Sanofi SA pays a 6.01% dividend while Coursera Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Coursera Inc for 47 Days and Sanofi SA for 94 Days on average.
| COUR | SNY | |
|---|---|---|
Market Cap | $1.39B | $95.18B |
Volume | 9,728,980 | 2,995,646 |
Sector | Consumer Staples | Health |
52-Week High | $10.73 | $52.34 |
52-Week Low | $4.64 | $39.51 |
Typical Hold Time | 47 Days | 94 Days |
Enterprise Value | $648.49M | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coursera (COUR) trades at $5.11, down 0.2% with bearish technical signals despite positive analyst sentiment. The company shows improving revenue growth from $524M in 2022 to $758M in 2025, though net losses persist at -$51M. Recent news highlights strong institutional interest with Deutsche Bank acquiring 1.7M shares and unusual options activity indicating bullish speculation. The stock faces technical resistance at $5 with RSI suggesting potential overbought conditions near-term.
While analyst consensus remains bullish with a $7.40 price target (44% upside), execution risks from ongoing losses and competitive pressures in edtech warrant caution. The company's Project Helix AI platform and 44% subscriber growth provide catalysts, but profitability challenges and integration costs from recent acquisitions present headwinds for investor returns.
SNY trades at $40.2, up 1.62% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $46.72B in 2025, and net income improved to $7.81B. Analyst consensus is mixed, with 44% buy ratings. Recent news highlights a major immunology alliance expansion with Regeneron, valued up to $8B, signaling growth initiatives beyond Dupixent.
The outlook for SNY is cautiously optimistic, driven by earnings momentum and strategic partnerships, but faces risks from patent expirations and volatile cash flows. Investment opportunity lies in pipeline diversification and cost management, while investors should monitor competitive pressures and R&D execution. The stock's current valuation metrics suggest reasonable pricing relative to peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Coursera Inc
Coursera Inc is a global online learning platform that offers anyone, anywhere access to online courses and degrees from world-class universities and companies. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The platform will contain a catalog of high-quality content and credentials, content developed by leading university and industry partners, data and machine learning drive personalized Learning, effective marketing, and skills Benchmarking and others.
Read more on COUR →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
